博瑞医药(688166) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was CNY 1,052,408,590.87, representing a 34.00% increase compared to 2020[24]. - The net profit attributable to shareholders for 2021 was CNY 243,951,048.34, reflecting a 43.60% growth year-over-year[24]. - The net cash flow from operating activities for 2021 was CNY 176,075,346.56, an increase of 13.28% from the previous year[24]. - The basic earnings per share for 2021 was CNY 0.60, up 46.34% from CNY 0.41 in 2020[24]. - The company's gross profit margin was 56.23% during the reporting period[152]. - The company achieved a total revenue of 69,980 million RMB, with a net profit of 33,662.05 million RMB, indicating a strong financial performance[125]. R&D and Innovation - The company invested CNY 173.29 million in R&D, a 23.04% increase year-on-year, representing 16.47% of operating revenue[41]. - The company has submitted 15 new domestic patent applications and received 29 new domestic patent authorizations, totaling 326 patent applications, with 324 being invention patents[46]. - The company has developed multiple advanced drug technology platforms, including fermentation semi-synthesis, multi-chiral drugs, non-biological macromolecules, inhalation formulations, and conjugated drugs, covering various therapeutic areas[87][88][89][92][93][97]. - The innovative drug BGC0228 has received IND approval and is currently in Phase 1 clinical trials[41]. - The company reported a total R&D investment of approximately ¥173.29 million, representing a 23.04% increase from the previous year[108]. Market and Sales - The company’s main business revenue from product sales was CNY 927,795,300, which is a 38.38% increase year-on-year[165]. - The company’s foreign sales accounted for a significant portion of revenue, with foreign sales revenue reaching CNY 488,723,891.19, a 70.01% increase[169]. - The company is actively pursuing market expansion strategies, including partnerships for technology support and profit-sharing models with international pharmaceutical companies[133]. - The company has established a strong position in the pharmaceutical supply chain, allowing it to enjoy profit-sharing from clients' sales of formulation products[73]. Corporate Governance and Compliance - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report, assuming legal responsibility for any misstatements or omissions[4]. - The company has received a standard unqualified audit report from the accounting firm Tianye[6]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[9]. - The company has not disclosed any special arrangements for corporate governance[9]. Risks and Challenges - The company has detailed various risks faced during its operations in the report, emphasizing the importance of risk awareness for investors[5]. - The company faces potential risks from policy changes in the pharmaceutical industry, particularly regarding volume-based procurement and consistency evaluations[158]. - The company is exposed to risks from potential changes in tax policies that could increase income tax expenses[147]. - The company must maintain a stable and skilled technical talent team to sustain its competitive edge in the industry[140]. Production and Capacity - The company’s production capacity utilization rate remained high in 2021, with ongoing optimization of processes to reduce production costs[47]. - The company’s Taixing raw material and formulation production base has a planned capacity of 3,450 kg, with construction progressing to equipment validation stage[49]. - The company has invested a total of RMB 46.5 million in the Suzhou inhalation and other chemical drug formulation base project, with an annual design capacity of 64 million units[51]. Strategic Investments - The company has made equity investments in several innovative biotech firms, including RMB 20 million in Beijing InnoRuiKang and RMB 20 million in Suzhou Laitacon[55]. - The company invested $3.3 million in the Boryeong Indonesia project, which has a planned raw material capacity of approximately 3,677 kg, with 99% of civil engineering completed[54]. Product Development - The company has obtained production approval for Olanzapine injection and has passed the consistency evaluation for Micafungin sodium injection in China[45]. - The company’s innovative drug BGC0228 has received IND approval and is currently in Phase 1 clinical trials, while other drugs are in preclinical research stages[60]. - The company aims to complete clinical research for the new drug application of the Colchicine patch in the short term[119].